India, April 15 -- Shares of Mural Oncology plc (MURA) doubled on Tuesday morning after the clinical-stage immuno-oncology company announced plans to explore strategic alternatives.
MURA is currently trading at $2.4600, up $1.4300 or 138.8350%, on a volume of 115.9 million shares, above average volume of 275 thousand, on the Nasdaq. The stock opened its trading at $2.3050 after closing Monday at $1.0300. The stock has traded between $0.9500 and $4.7400 in the past 52-week period.
Mural Oncology announced that following review of data from its phase 2 ARTISTRY-6 trial in melanoma and previously announced results from the phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer, the company is discontinuing all clinical development of ...